In vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria.
The in vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, was compared with those of DU-6859a, cefditoren, ampicillin/sulbactam and clindamycin against a variety of anaerobic bacteria. R-95867 inhibited 90% of anaerobic strains at </=2 mg/L. In general, R-95867 was 2- to 4-fold less active than DU-6859a but more active than other agents tested against strains of peptostreptococci, clostridia, the Bacteroides fragilis group, Porphyromonas spp. and fusobacteria. R-95867 was stable to hydrolysis by beta-lactamase type 2e derived from B. fragilis, Prevotella bivia and Prevotella intermedia, but unstable to hydrolysis by carbapenemase from B. fragilis.
Kato
N
N
Institute of Anaerobic Bacteriology, Gifu University School of Medicine, 40 Tsukasa-machi, Gifu 500-8705, Japan. nk19@cc.gifu-u.ac.jp
Tanaka
K
K
Kato
H
H
Watanabe
K
K
D001421:Bacteria, Anaerobic / Q000187:drug effects*; D015780:Carbapenems / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology*; D003470:Culture Media; D004352:Drug Resistance, Microbial; D006863:Hydrogen-Ion Concentration; D008826:Microbial Sensitivity Tests; D011355:Prodrugs / Q000493:pharmacokinetics / Q000494:pharmacology*; D001618:beta-Lactamases / Q000378:metabolism
D015780:Carbapenems; D003470:Culture Media; D011355:Prodrugs; C109885:R 95867; D001618:beta-Lactamases; C107030:CS 834